InvestSMART

PharmAust Limited (ASX: PAA) - Announcements

Current share price for PAA : $0.230 0.015 (6.98%)+

ASX company news and announcements for PharmAust Limited (PAA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PharmAust Limited (PAA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PharmAust Limited (PAA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PharmAust Limited (PAA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- AGM Presentation 21 Oct 2021 4:24PM $0.096 $0.230 risen by 139.58%
- MPL Manufacturing and Human Trials Update 21 Oct 2021 8:45AM $0.097 $0.230 risen by 137.11%
- Following Extension of Survival, PAA Prepares Phase 3 Trial 18 Oct 2021 8:20AM $0.094 $0.230 risen by 144.68%
- Proposed issue of securities - PAA 1 Oct 2021 2:07PM $0.088 $0.230 risen by 161.36%
- Prospectus 1 Oct 2021 2:04PM $0.088 $0.230 risen by 161.36%
- Entitlement Options Offer 1 Oct 2021 1:55PM $0.088 $0.230 risen by 161.36%
- Notice of Annual General Meeting/Proxy Form 17 Sep 2021 2:21PM $0.088 $0.230 risen by 161.36%
- Letter to shareholders re AGM 17 Sep 2021 2:15PM $0.088 $0.230 risen by 161.36%
- Broker Briefing Presentation Tech & Biotech Investor Webinar 9 Sep 2021 8:19AM $0.092 $0.230 risen by 150%
- Broker Briefing Investor Webinar 7 Sep 2021 9:35AM $0.086 $0.230 risen by 167.44%
- Epichem Completes Final Loan Repayment 31 Aug 2021 8:05AM $0.084 $0.230 risen by 173.81%
- Change of Director's Interest Notice 24 Aug 2021 3:05PM $0.083 $0.230 risen by 177.11%
- Application for quotation of securities - PAA 24 Aug 2021 3:02PM $0.083 $0.230 risen by 177.11%
- Appendix 4G & Corporate Governance Statement 18 Aug 2021 3:25PM $0.089 $0.230 risen by 158.43%
- Appendix 4E & Full Year Statutory Accounts 18 Aug 2021 3:20PM $0.089 $0.230 risen by 158.43%
- Epichem Completes Build of OHD Benchtop Flow Reactor 3 Aug 2021 8:18AM $0.091 $0.230 risen by 152.75%
- Virtual Investor Briefing 30 Jul 2021 10:03AM $0.090 $0.230 risen by 155.56%
- Appendix 4C and Quarterly Update 28 Jul 2021 8:26AM $0.105 $0.230 risen by 119.05%
- Monepantel and monepantel sulfone COVID-19 anti-viral update 26 Jul 2021 10:26AM $0.096 $0.230 risen by 139.58%
- PharmAust files patent for monepantel in viral diseases 22 Jul 2021 8:16AM $0.096 $0.230 risen by 139.58%
- PharmAust and WEHI to Investigate HTLV-1 Viral Infections 12 Jul 2021 8:23AM $0.095 $0.230 risen by 142.11%
- Science Week Conference Presentation 9 Jul 2021 8:19AM $0.094 $0.230 risen by 144.68%
- PharmAust establishes monepantel GMP tablet stability 7 Jul 2021 8:22AM $0.091 $0.230 risen by 152.75%
- Phase IIb Dog Trial Achieves Interim Clinical Endpoints 28 Jun 2021 8:29AM $0.088 $0.230 risen by 161.36%
- PharmAust receives ethics approval for Phase I trial in MND 2 Jun 2021 8:23AM $0.092 $0.230 risen by 150%

276 - 300 of 796 results

Page 12 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.